NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $15.90 -0.57 (-3.46%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$15.83▼$16.8050-Day Range N/A52-Week Range$11.28▼$19.80Volume33,572 shsAverage Volume23,360 shsMarket Capitalization$713.75 millionP/E Ratio23.04Dividend YieldN/APrice Target$76.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsTrends Get Tectonic Therapeutic alerts: Email Address Tectonic Therapeutic MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside378.0% Upside$76.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.00) to ($4.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 starsMedical Sector399th out of 916 stocksBiological Products, Except Diagnostic Industry55th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingTectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTectonic Therapeutic has only been the subject of 2 research reports in the past 90 days.Read more about Tectonic Therapeutic's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TECX. Previous Next 0.0 Dividend Strength Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TECX. Previous Next 2.6 News and Social Media Coverage News SentimentTectonic Therapeutic has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tectonic Therapeutic this week, compared to 0 articles on an average week.Search Interest3 people have searched for TECX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Tectonic Therapeutic is held by insiders.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Tectonic Therapeutic are expected to grow in the coming year, from ($5.00) to ($4.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is 23.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is 23.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.25.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 7.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Tectonic TherapeuticAvrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.Read More TECX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TECX Stock News HeadlinesJune 26, 2024 | americanbankingnews.comPiper Sandler Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)June 24, 2024 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Now Covered by Analysts at TD CowenSee More Headlines Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TECX CUSIPN/A CIKN/A Webwww.avrobio.com Phone617-914-8420FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$76.00 High Stock Price Target$76.00 Low Stock Price Target$76.00 Potential Upside/Downside+378.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.69 Trailing P/E Ratio23.04 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.52% Return on Assets-47.13% Debt Debt-to-Equity RatioN/A Current Ratio26.17 Quick Ratio26.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book7.46Miscellaneous Outstanding Shares44,890,000Free Float40,764,000Market Cap$713.75 million OptionableN/A Beta2.55 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key CompetitorsArcellxNASDAQ:ACLXTwist BioscienceNASDAQ:TWSTSpringWorks TherapeuticsNASDAQ:SWTXADMA BiologicsNASDAQ:ADMAApogee TherapeuticsNASDAQ:APGEView All Competitors TECX Stock Analysis - Frequently Asked Questions Should I buy or sell Tectonic Therapeutic stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tectonic Therapeutic in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TECX shares. View TECX analyst ratings or view top-rated stocks. What is Tectonic Therapeutic's stock price target for 2024? 2 Wall Street research analysts have issued 1-year target prices for Tectonic Therapeutic's shares. Their TECX share price targets range from $76.00 to $76.00. On average, they anticipate the company's stock price to reach $76.00 in the next twelve months. This suggests a possible upside of 378.0% from the stock's current price. View analysts price targets for TECX or view top-rated stocks among Wall Street analysts. How have TECX shares performed in 2024? Tectonic Therapeutic's stock was trading at $16.10 at the start of the year. Since then, TECX shares have decreased by 1.2% and is now trading at $15.90. View the best growth stocks for 2024 here. When is Tectonic Therapeutic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TECX earnings forecast. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic (NASDAQ:TECX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.15) earnings per share for the quarter. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TECX) was last updated on 7/1/2024 by MarketBeat.com Staff From Our Partners1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But t...Banyan Hill Publishing | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
